Furthermore, Liu et al. [19] indicate that CPEB3 expression levels can be used as a potential biomarker for HCC patient stratification, and more importantly, results from Tang et al. [11] demonstrated that miR-452-3p directly targeted the CPEB3/EGFR axis and accelerated the proliferation and migration of liver cancer cells, which may provide a new therapeutic strategy for the treatment of HCC. Here, CPEB3 is linked to hepatocellular carcinoma.